drugset
drugset / Trial / NCT07707674

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

NCT07707674 ↗

Phase 1 Not yet recruiting 24 enrolled Evopoint Biosciences Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer

Timeline

Start
2026-07-30
Primary completion
2028-04-30
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XNW28012 Monoclonal antibody 2 mg/kg Intravenous
Subject XNW28012 Monoclonal antibody 2.4 mg/kg Intravenous

Indications

malignant pancreatic neoplasm